This was the stock's fifth consecutive day of losses.

Bristol-Myers Squibb Company (NYSE:BMY) is scheduled to announce Q2 earnings results on July 31st, before markets open.

Explore the exciting world of Bristol Meyers Squibb (NYSE: BMY) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the top low volatility healthcare stocks to buy now. On July 24, Goldman ...

Bristol Myers Squibb and Bain Capital launch a new biopharma firm focused on autoimmune disease treatments, starting with 5 ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives and advance five ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from ...

Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...

Novo Nordisk promoted Maziar Mike Doustdar to president and CEO, effective August 7. The Food and Drug Administration tapped newly appointed George Tidmarsh as acting Center for Biologics Evaluation ...

Bristol-Myers Squibb Company (NYSE:BMY) is included among the 10 Best and Safe Dividend Stocks to Buy Now. Bristol-Myers ...

Bristol Myers Squibb said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to meet the main ...